KAT2B is markedly overexpressed in FP-RMS tumor samples, and its genetic silencing or pharmacological inhibition reduces PAX3-FOXO1 protein levels, leading to decreased cell proliferation and impaired tumor growth in xenograft models [251]. This evidence concerns the gene FOXO1 and neoplasm.